Call for implementation of NICE guidance on CardioQ-ODM
23 January 2012
Deltex Medical Group plc, a developer of oesophageal Doppler
monitoring (ODM), has commented on the report on standards of surgical
care in the NHS by the UK National Confidential Enquiry into Patient
Outcome and Death (NCEPOD).
The report addresses a number of deficiencies in care commonly
experienced by high-risk surgical patients and makes recommendations
to improve fluid management before, during and after surgery.
The report calls specifically for the implementation of the NICE
Medical Technology Guidance that recommended CardioQ-ODM in NHS
patients undergoing major or high-risk surgery and in high-risk
patients undergoing lower risk surgery:
“Better intra-operative monitoring for high risk patients is
required. The evidence base supports the use of peri-operative
optimisation and this relies on extended haemodynamic monitoring.
NICE Medical Technology Guidance 31 relating to cardiac output
monitoring should be applied.”
CardioQ-ODM is the cardiac output monitoring technology
recommended by NICE in its guidance of 30 March 2011.
Ewan Phillips, Deltex Medical’s Chief Executive, commented:
"NCEPOD’s recommendation that the NICE guidance on CardioQ-ODM be
implemented provides powerful clinical backing to the accelerated
adoption of our products in the NHS. It follows the announcement on
Monday that the NHS has decided to launch a national drive to get
full implementation of fluid management during surgery into practice
across the NHS.”
1. National institute for Health and Clinical Excellence. Medical
Technology Guidance 3. CardioQ-ODM (oesophageal Doppler monitor)